Independent fund research. Built on SEC filings.

How we research funds

Mutual fund · International Stock · BNY Mellon / Dreyfus

BNY Mellon Global Real Return Fund Class A (DRRAX)

Ticker DRRAX · · Holdings as of Jul 31, 2026

Expense ratio
1.19%$119/yr per $10k
5-yr return
+2.6%annualized
1-yr return
+5.8%as of Dec 2025
Net assets
$844.7Mall share classes
Holdings
176

Bottom line

Is DRRAX a good fund? The bottom line

DRRAX is the Class A share class of BNY Mellon Global Real Return Fund, an actively managed international stock mutual fund from BNY Mellon / Dreyfus.

Annual fees run 1.19% — about $119 a year on every $10,000 invested, more expensive than 75% of international stock funds we track.

It returned +5.8% over one year, +2.6% a year over five years, +4.1% a year over ten (as of Dec 31, 2025, per its prospectus).

With $845 million in net assets and 176 holdings, its largest position is Merrill Lynch Bv (5.3%) and the top 10 make up 29.8% of the portfolio.

This share class carries a front-end sales charge of up to 5.75%; a no-load class or ETF alternative can avoid it.

What to watch

  • Expensive for its category (1.19%)
  • 5-year return in the bottom quarter of its category
  • Front-end sales load up to 5.75%
  • High turnover (119% a year) can mean more taxable distributions

Updated Nov 19, 2026

What DRRAX invests in

The fund seeks total return (consisting of capital appreciation and income).

To pursue its goal, the fund uses an actively-managed multi-asset strategy to seek to produce absolute or real returns with less volatility than major equity markets over a complete market cycle, typically a period of five years. The fund is not managed to a benchmark index. Rather than managing to track a benchmark index, the fund seeks to provide returns that are largely independent of market moves. The fund allocates its investments among global equities, bonds and cash, and, generally to a lesser extent, other asset classes, including real estate, commodities, currencies and alternative or non-traditional asset classes and strategies, primarily those accessed through derivative instruments. The fund may invest in, or otherwise have investment exposure to, the securities of companies of any market capitalization. The fund obtains investment exposure to these asset classes by…

From the fund's prospectus (filed Feb 26, 2026).

DRRAX performance

Fund calendar-year total returns, 2016–2025 2016: +2.4%; 2017: +3.8%; 2018: +0.9%; 2019: +11.5%; 2020: +9.5%; 2021: +6.8%; 2022: −8.6%; 2023: +2.6%; 2024: +7.5%; 2025: +12.3% +2% 2016 +4% 2017 +1% 2018 +11% 2019 +9% 2020 +7% 2021 −9% 2022 +3% 2023 +7% 2024 +12% 2025
Fund gain (+) Fund loss (−)
Average annual total returns
1 yr5 yr10 yr
DRRAX+5.8%+2.6%+4.1%
International Stock median+25.5%+6.4%+7.6%

Source: Fund prospectus, as of Dec 31, 2025

Full DRRAX performance history →

What DRRAX costs

On a $10,000 investment, DRRAX's 1.19% expense ratio costs about $119 a year. The prospectus estimates $1,985 in total costs over 10 years (assuming 5% annual returns). The median international stock fund charges 0.9%.

See the full DRRAX fee table →

DRRAX top 10 holdings

#Holding% of fund
1Merrill Lynch Bv5.35%
2Brazil, Federative Republic Of - Secretaria Do Tesouro Nacional4.34%
3United Mexican States - Secretaria De Hacienda Y Credito Publico3.75%
4Spdr Gold Trust GLD3.74%
5Ishares Gold Trust IAU3.32%
6South Africa, Republic Of - National Treasury2.58%
7Graniteshares Gold Trust BAR1.93%
8Dreyfus Institutional Preferred Money Market Funds1.60%
9Exxonmobil Holdings Corp XOM1.59%
10New Zealand, Her Majesty The Queen In Right Of - Debt Management Office Of The Treasury1.58%

Source: SEC Form N-PORT, period ended Jul 31, 2026

The top 10 make up 29.8% of the fund. See all top 25 holdings and asset mix →

Alternatives to DRRAX

More funds like DRRAX →

DRRAX FAQ

What is the expense ratio of DRRAX?
DRRAX's expense ratio is 1.19%, which works out to about $119 a year for every $10,000 invested. The prospectus estimates total costs of $1,985 over 10 years on a $10,000 investment (assuming 5% annual returns).
Is DRRAX a good investment?
It depends on your goals, but the data points to: expensive for its category (1.19%); 5-year return in the bottom quarter of its category; front-end sales load up to 5.75%; high turnover (119% a year) can mean more taxable distributions. This is general information, not personalized advice.
What does DRRAX hold?
DRRAX's largest holdings are Merrill Lynch Bv (5.3%), Brazil, Federative Republic Of - Secretaria Do Tesouro Nacional (4.3%), United Mexican States - Secretaria De Hacienda Y Credito Publico (3.7%), Spdr Gold Trust (3.7%), Ishares Gold Trust (3.3%). It holds 176 positions in total as of Jul 31, 2026 (SEC Form N-PORT).
What is DRRAX's 5-year return?
DRRAX returned +2.6% a year over the five years ending Dec 31, 2025, and +4.1% a year over ten years. Past performance does not guarantee future results.
Does DRRAX have a sales load?
Yes. DRRAX has a maximum front-end sales charge of 5.75%.
Who manages DRRAX?
DRRAX is offered by BNY Mellon / Dreyfus through BNY Mellon Advantage Funds, Inc..